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EDITORIAL
Assessing the evolution of atherosclerotic renal artery stenosis
Atherosclerotic narrowing of the renal arteries may result in
severe consequences including chronic renal ischemia, renal ar-
tery atheroembolism and renal vascular hypertension, all of which
may result in renal failure. Ischemic renal disease is increasingly
recognized as an important cause of progressive renal failure and
end-stage renal disease. The precise prevalence of atherosclerotic
renal artery disease (ARAD) leading to important nephropathy is
unknown as there are no population-based studies. Autopsy series
estimate that 25 to 30% of patients over the age of 60 have
atherosclerosis in the renal arteries, and angiographic studies in
patients undergoing angiography for extra-renal vascular disease
indicate that 18 to 42% have significant (. 50%) renal artery
stenosis [1]. As the median age of our incident end-stage renal
disease population continues to increase, ARAD is becoming an
increasingly important consideration in older individuals with
hypertension, renal insufficiency, or both.
The natural history of atherosclerotic ARAD has not been fully
elucidated. In this regard, Dean et al [2] reported that in 40% of
patients with atherosclerotic renal artery disease ($ 50% stenosis
by angiogram) in the age range of 40 to 65 years had a decline in
renal function, and 32% experienced a decrease in renal size ($
1.5 cm decrease in renal length) over a follow-up period of several
years. In this edition of Kidney International, Caps et al [3] report
new and important findings concerning the natural history of
ARD. They used the Doppler ultrasound technique to evaluate
ARAD in 214 kidneys from 118 patients. The patients were
referred for Doppler evaluation of the renal arteries because of
hypertension, renal insufficiency, or both. They utilized a criteria
of greater than a 1 cm reduction in renal size as indicating renal
atrophy and renal and aortic flow velocity as indicators of main
renal artery and parenchymal renal ischemia. Renal function was
assessed by serum creatinine measurements and patients were
followed prospectively for about three years with repeated mea-
sures of blood pressures, creatinine and Doppler ultrasound. The
key finding was that patients who had greater than 60% stenosis of
any renal artery had both a high cumulative incidence of renal
atrophy, and hypercreatininemia. Moreover, they found that the
subjects with less than 60% stenosis were also at an increased risk
of renal atrophy over this time period. Furthermore, they report
that the baseline of renal artery stenosis was an important
predictor of renal atrophy during follow-up, and systolic hyper-
tension was also an important predictor of progression for renal
disease. These observations confirm and extend previous reports
[2, 4] in patients with ARAD. Moreover, the authors found that
hypertension was associated with renal atrophy in both stenotic
and non-stenotic kidneys. This finding challenges the view that a
stenotic kidney is protected from the effects of systemic hyper-
tension in patients with ARAD. Thus, patients who have hyper-
tension and significant renal artery stenosis may continue to have
renal atrophy, suggesting that both hypertension and ischemia
play a role in the process of atrophy.
One-third of the patients in this study were being treated with
angiotension-converting enzyme inhibitors (ACEI) at baseline.
Importantly, the authors were unable to find any evidence that
ACEIs increased the risk of atrophy of the kidneys. Somewhat
surprising was the fact that they found no relationship between
baseline plasma lipid levels (including low density lipoprotein and
triglycerides) or serum creatinine and risk of atrophy. One might
expect that atherosclerosis, plasma lipid levels and baseline renal
function would be strongly associated given the increased risk of
atherosclerosis in azetemic and hypertensive populations. A close
look at the data in Table 3 of [3] indicates that the relative risk of
hyper-low density lipoprotein cholesterolemia was equal to the
relative risk for severity of renal artery stenosis, the former was
not significant, but the latter was significant. Perhaps this relates
to the fact that only a subset of patients had low density
liproprotein cholesterol levels measured at baseline.
The study has its shortcomings. First, the authors excluded
patients who had severe renal artery lesions, that is, those who
were presumed to have fibromuscular dysplasia with large or
multiple renal cysts. Patients with a kidney size of , 8.5 cm were
also excluded. In addition, technical limitations excluded three
patients from analysis. This point is important because visualizing
the renal vasculature can be a limitation of this technique [5]. On
the other hand, several studies indicate that in the hands of an
expert technician, the Doppler ultrasound is useful for both
diagnosis and follow-up of patients with known ARAD. Finally,
the gold standard for diagnosing and classifying renal artery
disease is still the renal angiogram. Therefore, angiography may
have improved the ability of the investigators to evaluate the
patients in the entire screened population. In this regard, it should
be noted that patients selected in the study were undergoing
Doppler ultrasound because of hypertension, azotemia, or both,
and were suspected to have atherosclerotic renal artery disease.
In summary, the study of Caps et al shows that patients with
atherosclerotic renal artery disease, particularly those with high-
grade stenosis and systolic hypertension, are at very high risk for
renal atrophy and renal failure. The findings also underscore the
fact that patients with lesser degrees (, 60%) of stenosis in the
renal artery are also at significant risk for renal atrophy and
azotemia. The findings imply that careful follow-up and control of
blood pressure and repeated measures of renal artery stenosis are
indicated in patients at risk for renal atherosclerosis. The appli-
cation of the Doppler ultrasound test is very useful for evaluating
and monitoring such patients. Improvements in the resolution of© 1998 by the International Society of Nephrology
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this technique and wider technical experience may improve the
use of this test for identifying and following patients at risk for
renal atrophy and progressive renal disease.
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